Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified Carboplatin/Vincristine + Endostatin in Pediatric OPG
NCT05278715Phase 2Recruiting
- Sponsor
- Beijing Sanbo Brain Hospital
- Start
- Apr 2022
- Primary completion
- Dec 2025
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of endostar in optic pathway glioma (OPG), sponsored by Beijing Sanbo Brain Hospital. Primary endpoint: Visual Acuity improvement rate at 3 years. Started Apr 2022; status: recruiting.
02
Drugs
endostar
03
Conditions
optic pathway glioma (OPG)
Beyond the preview
Go deeper on NCT05278715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05278715.